July 24th 2024
The FDA has granted a fast track designation to ozuriftamab vedotin for treating recurrent/metastatic head and neck cancer that progressed after prior therapies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Searching for the Key to Immunotherapy Response in Head and Neck Cancer
April 18th 2017Immunotherapy agents have shown great promise for the treatment of patients with head and neck cancer; however, only a small subset of patients reap these benefits. Thus, the question becomes: which patients are more likely to benefit from these therapies, and why?
Read More
Adjusting Dosing to Increase Efficacy of Cetuximab in Head and Neck Cancer
April 10th 2017Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses how dosing adjustments may be used to increase the efficacy of agents, such as cetuximab (Erbitux) in patients with head and neck cancer.
Watch
EMA Recommends Nivolumab for Approval in Head and Neck Cancer
March 24th 2017Nivolumab (Opdivo) has been recommended for approval by EMA’s Committee for Medicinal Products for Human Use for the treatment of patients with squamous cell cancer of the head and neck following progression on platinum-based therapy.
Read More
Globetrotting Head and Neck Cancer Show Hits 8 Countries
March 22nd 2017The International Federation of Head and Neck Oncologic Societies recently completed its fourth tour, with 8 experts in the field of head and neck oncology traveling to 8 countries over a month to offer continuing medical education courses on treatment paradigms and surgical techniques in head and neck cancer across the world.
Read More
Immunotherapy Making Its Mark on Head and Neck Cancer
March 22nd 2017Following the approval of 2 immunotherapy agents, pembrolizumab and nivolumab for the treatment of patients with head and neck cancer over the last 6 months, immunotherapy is making its mark on the treatment paradigm for HNC.
Read More
Researchers Identify Benefits of Stepped Psychosocial Support in Head and Neck Cancer
March 21st 2017Researchers in the Netherlands have found that using a gradual or “stepped” approach to providing psychosocial support for patients diagnosed with head and neck or lung cancers not only improves their quality of life but is also cost-effective.
Read More
An Overview of Head and Neck Cancer Treatment Strategies
March 17th 2017Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses current treatment strategies in head and neck cancer.
Watch
Concomitant Chemoradiotherapy Demonstrates Survival Benefit in Nasopharyngeal Carcinoma
March 16th 2017The addition of chemotherapy, either adjuvant or induction, to concomitant chemoradiotherapy (CRT) achieved a significantly high survival benefit for patients with locally advanced nasopharyngeal carcinoma.
Read More
Researchers Identify Criteria for Optimal Use of Adjuvant CRT in Head and Neck Cancer
March 15th 2017The number of positive lymph nodes is an appropriate selection factor in deciding adjuvant chemoradiotherapy use in some patients with locally advanced head and neck cancer, according to the results of a recent retrospective analysis .
Read More
Optimizing Patient Selection for Adjuvant CRT in Head and Neck Cancer is Key, Expert Says
March 14th 2017With the objective of identifying patients who would derive greater benefit from CRT, a recent retrospective, observational cohort study examined use and survival outcomes with adjuvant CRT in patients with resected locally advanced head and neck cancer.
Read More
Study Results for Nivolumab and Pembrolizumab in Head and Neck Cancer
February 20th 2017Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses results of studies that investigated nivolumab and pembrolizumab in head and neck cancer.
Watch
Biomarker May Predict Recurrence in HPV+ Oropharyngeal Cancer
February 16th 2017Matthew E. Spector, MD, discusses a new biomarker study which found that patients whose oropharyngeal cancer recurred had higher levels of antibodies for 2 proteins, E6 and E7, which are found in HPV-driven cancers.
Read More
Individualized Bioselection Treatment Improves Survival Rates in Laryngeal Cancer
February 16th 2017A novel approach has been developed by researchers at the University of Michigan to treating patients with advanced laryngeal cancer with the hope of improving historical survival rates of 50% to 60% in this setting.
Read More
Missing Tumor-Specific Mutations Lead to Increased Resistance to Checkpoint Inhibitors
February 10th 2017Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that acquired resistance to checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.
Read More
Expert Addresses Need for Speedier Trial Design in Anaplastic Thyroid Cancer
November 22nd 2016Immunotherapy has potential in anaplastic thyroid cancer, but it presents a challenge because of the length of time it takes to have an effect. Maria Cabanillas, MD, discusses an upcoming clinical trial that is combining immunotherapy with targeted therapy, that may offer a solution.
Read More
Immunotherapy Success Is Paving the Way for "Colder" Tumors, Allison Says
November 1st 2016James Allison, PhD, discusses exciting advancements in immunotherapy combinations, the potential synergistic effects of radiation with immunotherapies, and considerations that must be made when combining other agents with immunotherapy.
Read More
Pembrolizumab in HNSCC Only Scratches the Surface of Immunotherapy Potential, Expert Says
October 27th 2016An expert discusses the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.
Read More
Adding Immunotherapy to Head and Neck Cancer Treatment Fails to Improve PFS
October 19th 2016Adding a Toll-like receptor 8 agonist (TLR8) to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) failed to improve progression-free survival (PFS).
Read More
KRAS-Variant HNSCC Outcomes May Improve With Cetuximab
October 13th 2016Patients with head and neck cancer whose disease is associated with <em>KRAS</em> variant had significantly better progression-free survival (PFS) and overall survival (OS) when treated with the monoclonal antibody cetuximab (Erbitux), according to findings of a retrospective analysis of a randomized trial.
Read More
Fixed-Dose Pembrolizumab Yields Durable Responses in HNSCC
October 5th 2016The FDA-approved fixed dose of 200 mg of pembrolizumab administered once every 3 weeks yielded durable responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC), according to results from an expansion cohort of the phase Ib KEYNOTE-012 trial.
Read More